Artificial intelligence is no longer emerging—it's here, reshaping how dentists diagnose, document, and communicate with patients. And increasingly, it's how insurance companies review claims. Drawing on experience in FDA and CMS policy development and current leadership at Overjet, global leading dental AI company with multiple FDA clearances, this session cuts through the hype to address what clinicians actually need to know.

We'll demystify FDA clearance—what it requires, what it doesn't, and how to distinguish rigorously validated tools from marketing claims. We'll explore how AI detects subtle radiographic changes that are difficult to perceive, supports longitudinal disease tracking, and generates evidence-based documentation that can strengthen insurance approvals. You'll see how AI becomes the connective tissue of a modern practice: from first patient impression, through clinical conversation with color-coded visuals, to post-visit follow-through.

Early adopters report reduced decision fatigue, streamlined documentation, and improved case acceptance. But successful implementation requires more than software—it demands calibration, team training, and thoughtful change management. We'll also address data governance, transparency, and clinician oversight so you can adopt responsibly.

By engaging critically with these tools now, you position your practice for sustainable success—and gain the knowledge to shape the policy conversations that will define AI's future in dentistry.

Upon completion of this session, attendees should be able to:

Explain FDA clearance requirements for dental AI, including performance validation, risk classification, and post-market surveillance.

Describe how AI detects subtle radiographic findings and supports longitudinal disease tracking to strengthen clinical decision-making.

Identify how AI-generated documentation can improve insurance claim approvals and recognize that payers are increasingly using AI too.

• Apply AI-powered visualization tools to enhance patient communication, shared decision-making, and case acceptance.

• Evaluate implementation requirements—including calibration, team training, and change management—for successful AI adoption.

• Assess principles of data governance, transparency, and clinician oversight essential for responsible AI integration.

Lecture up to 30 minutes

AGS Subject code 550, Practice Management & Human Relations

Dr. Natalia Chalmers is a board-certified pediatric dentist and 2025 AAPD Pediatric Dentist of
the Year, oral health policy expert, and public health advocate bringing over 20 years of clinical,
research, and regulatory experience to the forefront of dental innovation. As the Chief Dental
Officer and Head of Clinical Innovation at Overjet, she leverages data-driven insights to
transform dental healthcare delivery and ensure access to high-quality, patient-centered care.
Previously, Dr. Chalmers made history as the first Chief Dental Officer in the Office of the
Administrator at the Centers for Medicare & Medicaid Services (CMS). There, she led
groundbreaking initiatives to expand dental coverage, established the first CMS dental claims
processing system, and implemented new quality measurements that reshaped the national
conversation on oral health. Her public sector leadership also includes tenure as a Dental
Officer at the US Food and Drug Administration (FDA).

A recognized expert in clinical analytics, Dr. Chalmers is dedicated to advocating for the role of
health policy across the lifespan—viewing dental well-being as intrinsic to whole-person care.
Dr. Chalmers completed her Doctor of Dental Surgery degree at the Faculty of Dental Medicine
of the Medical University of Sofia, a residency in pediatric dentistry at the University of Maryland
School of Dentistry, and a Ph.D. in oral microbiology from the Graduate Partnerships Program
of the University of Maryland School of Dentistry and the National Institute for Dental and
Craniofacial Research at the National Institutes of Health, Post-doctoral Fellowship at the ADA
Forsyth Institute, and Clinical Research Fellowship at the National Institute for Dental and
Craniofacial Research, National Institutes of Health.  Dr. Chalmers holds a Master’s degree in
Clinical Research from Duke Medical University and a Certificate in Drug Development and
Regulatory Science from the University of California, San Francisco School of Pharmacy.